These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30897608)

  • 21. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
    Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
    Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
    [No Abstract]   [Full Text] [Related]  

  • 23. Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
    Heczey A; Louis CU
    Discov Med; 2013 Dec; 16(90):287-94. PubMed ID: 24333408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
    Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
    Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
    Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
    Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives].
    Valteau-Couanet D; Minard-Colin V; Pasqualini C
    Med Sci (Paris); 2019 Dec; 35(12):997-1000. PubMed ID: 31903906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
    Slatnick LR; Jimeno A; Gore L; Macy ME
    Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
    Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy with GD2 specific monoclonal antibodies.
    Cheung NK; Medof ME; Munn D
    Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
    [No Abstract]   [Full Text] [Related]  

  • 30. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting
    Fleurence J; Fougeray S; Bahri M; Cochonneau D; Clémenceau B; Paris F; Heczey A; Birklé S
    J Immunol Res; 2017; 2017():5604891. PubMed ID: 28154831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-GD2 immunoliposomes loaded with oxamate for neuroblastoma.
    Panosyan WS; Panosyan DE; Koster J; Panosyan EH
    Pediatr Res; 2023 Aug; 94(2):458-461. PubMed ID: 36788290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
    Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New immunotherapeutic strategies for the treatment of neuroblastoma.
    Croce M; Corrias MV; Rigo V; Ferrini S
    Immunotherapy; 2015; 7(3):285-300. PubMed ID: 25804480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma.
    Cheung NK; Miraldi FD
    Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022
    [No Abstract]   [Full Text] [Related]  

  • 38. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promising therapeutic targets in neuroblastoma.
    Matthay KK; George RE; Yu AL
    Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
    Horwacik I; Rokita H
    Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.